Patents by Inventor Kyu Won Kim

Kyu Won Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10887109
    Abstract: Disclosed is an electronic device.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: January 5, 2021
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Moon Soo Chang, Kyu Won Kim, Min Ho Kim, Jong Hoon Park, In Jun Son, Tae In An, So Hyeon Jeon, In Myung Choi, Ji Yoon Park, Dong Hyun Yeom
  • Publication number: 20200353978
    Abstract: A system and method for detecting a hands-off state of a steering wheel may include acquiring, by a controller, a steering torque, a steering angle and a steering angular speed while driving of a vehicle, determining, by the controller, a variance value of the steering angular speed through cumulation for a designated time, determining, by the controller, a difference value between a steering angular speed estimated through a steering system model determined on an assumption that the steering wheel is in the hands-off state and a measured steering angular speed through cumulation for a designated time, when the variance value of the steering angular speed is less than a first threshold value, and divisionally determining, by the controller, whether or not the steering wheel is in the hands-off state or in the hands-on state according to the difference value between the measured and estimated steering angular speeds.
    Type: Application
    Filed: September 30, 2019
    Publication date: November 12, 2020
    Inventors: Dong Hyun Hwang, Jin Hyuck Heo, Kyu Won Kim
  • Publication number: 20190058596
    Abstract: Disclosed is an electronic device.
    Type: Application
    Filed: June 15, 2018
    Publication date: February 21, 2019
    Inventors: Moon Soo CHANG, Kyu Won KIM, Min Ho KIM, Jong Hoon PARK, In Jun SON, Tae In AN, So Hyeon JEON, In Myung CHOI, Ji Yoon PARK, Dong Hyun YEOM
  • Patent number: 9745280
    Abstract: A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1?, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: August 29, 2017
    Assignee: SNU R&DB FOUNDATION
    Inventors: Young-Ger Suh, Hongchan An, Seungbeom Lee, Kyu-Won Kim, Ho-Young Lee, Sang Geon Kim, Jeong Hun Kim
  • Publication number: 20160340331
    Abstract: A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1?, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.
    Type: Application
    Filed: July 22, 2016
    Publication date: November 24, 2016
    Applicant: SNU R&DB FOUNDATION
    Inventors: Young-Ger SUH, Hongchan AN, Seungbeom LEE, Kyu-Won KIM, Ho-Young LEE, Sang Geon KIM, Jeong Hun KIM
  • Patent number: 9138474
    Abstract: The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: September 22, 2015
    Assignee: SNU R&DB FOUNDATION
    Inventors: Kyu-Won Kim, Hyo-Jong Lee, Bum Ju Ahn
  • Patent number: 9089554
    Abstract: The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical composition of the invention. The central nervous system diseases contemplated within the invention include post-traumatic stress syndrome, stroke, and spinal injury.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: July 28, 2015
    Assignee: SNU R&B Foundation
    Inventors: Kyu-Won Kim, Jong-Ho Cha
  • Publication number: 20150183797
    Abstract: The present invention relates to a compound inhibiting Hsp90 and a pharmaceutical composition comprising the same as an active ingredient. The compounds represented by formula 1 and formula 2 of the present invention suppress the expression of Hsp90 so that they can inhibit the accumulation of HIF-1?, the Hsp90 client protein, and also efficiently inhibit the activation of VEGF. In addition, these compounds display low cytotoxicity, so that they can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.
    Type: Application
    Filed: January 2, 2015
    Publication date: July 2, 2015
    Applicant: SNU R&DB FOUNDATION
    Inventors: Young-Ger SUH, Dong-Jo CHANG, Hongchan AN, Kyu-Won KIM, Young-Myeong KIM, Ho-Young LEE
  • Publication number: 20140037640
    Abstract: The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease.
    Type: Application
    Filed: October 4, 2013
    Publication date: February 6, 2014
    Applicant: SNU R&DB FOUNDATION
    Inventors: Kyu-Won KIM, Hyo-Jong LEE, Bum Ju AHN
  • Patent number: 8618072
    Abstract: The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: December 31, 2013
    Assignee: SNU R&DB Foundation
    Inventors: Kyu-Won Kim, Hyo-Jong Lee, Bum Ju Ahn
  • Publication number: 20130330361
    Abstract: The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical composition of the invention. The central nervous system diseases contemplated within the invention include post-traumatic stress syndrome, stroke, and spinal injury.
    Type: Application
    Filed: February 21, 2012
    Publication date: December 12, 2013
    Applicant: SNU R&DB Foundation
    Inventors: Kyu-Won Kim, Jong-Ho Cha
  • Patent number: 8495229
    Abstract: Provided is a method of defending against a battery exhaustion attack on a wireless communication device. The method includes: determining whether a battery exhaustion attack against a first wireless communication device occurred based on a connection state between the first wireless communication device and at least one second wireless communication device; if it is determined to be a battery exhaustion attack against the first wireless communication device, defending the battery exhaustion attack using a communication module of the first wireless communication device; and if it is determined that the is no a battery exhaustion attack against the first wireless communication device, performing communication between the first wireless communication device and the at least one second wireless communication device according to the connection state.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: July 23, 2013
    Assignee: Samsung Electronics Co., Ltd.
    Inventor: Kyu-won Kim
  • Patent number: 8422996
    Abstract: Provided is a system for providing a silent advertisement that includes a multimedia message server for generating a multimedia message containing at least one piece of silent advertisement data and transmitting the multimedia message to an arbitrary mobile terminal, and the mobile terminal for receiving the multimedia message, detecting and storing the silent advertisement data contained in the multimedia message without notifying a user, and if a current operational state of the mobile terminal corresponds to a pre-set silent advertisement output condition, outputting the silent advertisement data. Accordingly, provided is a method, apparatus, and system for silently transmitting advertisement data to a mobile terminal of a user even if the user does not request to receive advertisements in advance, which are used by a communication provider to modify advertisement data stored in advance in the mobile terminal of the user in response to a request of a sponsor.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: April 16, 2013
    Assignee: Samsung Electronics Co., Ltd
    Inventor: Kyu-Won Kim
  • Patent number: 8395701
    Abstract: Provided is an operating voltage scaling method for a portable terminal. The method includes, if reproduction of a moving image is requested, acquiring DYNamicity (DYN) of the reproduction-requested moving image, determining whether frame skipping is possible for the moving image according to the acquired DYN of the moving image, and if it is determined that frame skipping is possible for the moving image, supplying a low operating voltage to a controller of the mobile terminal to control the mobile terminal to operate with a low-speed clock, and reproducing the moving image while skipping a frame.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: March 12, 2013
    Assignees: Samsung Electronics Co., Ltd, Seoul National University R&DB Foundation
    Inventors: Jungwon Kim, Jaejin Lee, Kyu-Won Kim, Sung-Kwan Heo
  • Publication number: 20110250193
    Abstract: The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease.
    Type: Application
    Filed: June 16, 2011
    Publication date: October 13, 2011
    Applicant: SNU R&DB FOUNDATION
    Inventors: Kyu-Won KIM, Hyo-Jong LEE
  • Publication number: 20110171661
    Abstract: Provided are a method of diagnosing the recurrence or possibility of recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery and a method of screening a drug for preventing the recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery and treating hepatocellular carcinoma. Specifically, the recurrence or possibility of recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery is diagnosed and a drug for preventing the recurrence of hepatocellular carcinoma after surgery and treating hepatocellular carcinoma is screened, by measuring expression levels of a metastatic tumor antigen 1 or metastasis associated 1 (MTA1) protein in a biological sample taken from a patient in which hepatocellular carcinoma recurs or is likely to recur after hepatocellular carcinoma surgery and comparing the measured expression levels of the MTA1 protein with those of a normal control group.
    Type: Application
    Filed: August 26, 2008
    Publication date: July 14, 2011
    Inventors: Young Hwa Chung, Eun Sil Yu, Soo Hyung Ryu, Kyu Won Kim, Jeong A Kim
  • Publication number: 20110162092
    Abstract: The present invention relates to a composition comprised of AKAP12 (A-Kinase anchoring protein 12) and to uses of AKAP12 mutant zebrafish as an animal model. More particularly, the following characteristics are noted in the present AKAP12 mRNA knockdown zebrafish: crooked or shortened tail, inability to move normally, non-uniform micro-vasculature in the brain, and change in heart shape with non-uniform and weak heartbeats. It also has various circulatory and genetic defects, such as hemorrhage from the ventricles of the heart, brain, and retina. All of these defects can be cured with AKAP12 injection. Therefore, AKAP12 can be used as an active component for a composition to prevent and heal circulatory and genetic defects that are caused by AKAP12 deficiency, and as a hemorrhage inhibitor. Further, the AKAP12 deficient mutant zebrafish can be useful as an animal model for verification of effectiveness of treatment for genetic defects in the circulatory system.
    Type: Application
    Filed: June 12, 2009
    Publication date: June 30, 2011
    Applicant: SNU RDB FOUNDATION
    Inventors: Kyu-Won Kim, Hyouk-Bum Kwon
  • Publication number: 20110153855
    Abstract: Provided is a method of defending against a battery exhaustion attack on a wireless communication device. The method includes: determining whether a battery exhaustion attack against a first wireless communication device occurred based on a connection state between the first wireless communication device and at least one second wireless communication device; if it is determined to be a battery exhaustion attack against the first wireless communication device, defending the battery exhaustion attack using a communication module of the first wireless communication device; and if it is determined that the is no a battery exhaustion attack against the first wireless communication device, performing communication between the first wireless communication device and the at least one second wireless communication device according to the connection state.
    Type: Application
    Filed: July 23, 2010
    Publication date: June 23, 2011
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventor: Kyu-won KIM
  • Patent number: 7960345
    Abstract: The present invention relates to an angiogenesis inhibitor comprising meteorin as an active ingredient that is highly expressed in astrocytes of the brain and retina in the late embryonic stage and after the birth of a mouse. It is in particular highly detected in astrocyte endfeet surrounding blood vessels and promotes the expression of thrombospondin-1/-2 (TSP-1/-2) via autocrine pathway and thus inhibits angiogenesis. The meteorin of the present invention can be effectively used for pharmaceutical compositions and health foods that prevent vascular diseases by inhibiting angiogenesis.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: June 14, 2011
    Assignee: Snu R&DB Foundation
    Inventor: Kyu-Won Kim
  • Publication number: 20110123538
    Abstract: The present invention relates to a composition comprising a Ninjurin 1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin 1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin 1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin 1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease.
    Type: Application
    Filed: December 24, 2008
    Publication date: May 26, 2011
    Applicant: SNU R&DB FOUNDATION
    Inventors: Kyu-Won Kim, Hyo-Jong Lee